Keyphrases
Cost-effectiveness
100%
Sub-Saharan Africa
100%
HIV Transmission
100%
Seroprevalence
100%
Single-dose Nevirapine
100%
Cases Averted
100%
Disability-adjusted Life Years
80%
Targeted Treatment
60%
Nevirapine
60%
Universal Treatment
60%
Pregnant Women
40%
Human Immunodeficiency Virus Type 1 (HIV-1)
40%
Counseling
40%
Multiple Dose
20%
Treatment Options
20%
Short Course
20%
Public Health Impact
20%
Program Cost
20%
Public Health Interventions
20%
Sensitivity Analysis
20%
Cost-effectiveness Ratio
20%
Antiretroviral Regimens
20%
Reasonable Cost
20%
Associated Costs
20%
Multivariate Sensitivity Analysis
20%
Public Health Priority
20%
Low Seroprevalence
20%
HIV-1 Testing
20%
Pediatric HIV-1
20%
Medicine and Dentistry
Health Care Cost
100%
Cost-Effectiveness Analysis
100%
Human Immunodeficiency Virus
100%
Single Drug Dose
100%
Nevirapine
100%
Seroprevalence
60%
Disability Adjusted Life Years
40%
Public Health
30%
Targeted Therapy
30%
Pregnant Woman
20%
Pediatrics
10%
HIV Test
10%
Treatment Option
10%
Biochemistry, Genetics and Molecular Biology
Human Immunodeficiency Virus 1
100%
Seroprevalence
100%
Single Drug Dose
100%
Disability-Adjusted Life Year
83%
Economics, Econometrics and Finance